David (Propofol Wannabes) Versus Goliath (Propofol): AZD-3043 Goes Up Against the Giant!

Affiliations

¹ From the Nuffield Department of Anaesthetics, University of Oxford, Oxford, United Kingdom; and Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah.

Editorial

John W Sear et al. Anesth Analg. 2015 Oct.

. 2015 Oct;121(4):849-851.

doi: 10.1213/ANE.0000000000000904.

¹ From the Nuffield Department of Anaesthetics, University of Oxford, Oxford, United Kingdom; and Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah.

No abstract available

References

1. Jensen V, Rappaport BA. The reality of drug shortages—the case of the injectable agent propofol. N Engl J Med. 2010;363:806–7
1. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, Perrotta DM, Burwen DR, Welbel SF, Pegues DA, Stroud L, Zeitz PS, Jarvis WR. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med. 1995;333:147–54
1. Gutelius B, Perz JF, Parker MM, Hallack R, Stricof R, Clement EJ, Lin Y, Xia GL, Punsalang A, Eramo A, Layton M, Balter S. Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. Gastroenterology. 2010;139:163–70
1. Johnson KB, Egan TD, Kern SE, White JL, McJames SW, Syroid N, Whiddon D, Church T. The influence of hemorrhagic shock on propofol: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology. 2003;99:409–20
1. Conway CM, Ellis DB. Propanidid. Br J Anaesth. 1970;42:249–54